{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:17:18Z","timestamp":1771669038366,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infection with extensive-drug-resistant (XDR) carbapenem-resistant (CR) Gram-negative bacteria (GNB) are viewed as a serious threat to human health because of the limited therapeutic options. This imposes the urgent need to find agents that could be used as adjuvants or combined with carbapenems to enhance or restore the susceptibility of XDR CR- GNB. Therefore, this study aimed to examine the effect of propranolol (PR) in combination with Meropenem (MEM) on the susceptibility profile of XDR CR-GNB recovered from severely infected patients as well as to evaluate combining MEM with either tigecycline (TGC) or amikacin (AK).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 59 non-duplicate CR- GNB were investigated for carbapenemase production by the major phenotypic methods. Molecular identification of five major carbapenemase-coding genes was carried out using polymerase chain reactions (PCR). Antimicrobial susceptibility tests were carried out using standard methods. Phenotypic and genotypic relatedness was carried out using the heatmap and ERIC PCR analysis. PR, 0.5 -1\u00a0mg\/mL against the resulting non-clonal XDR CR-GNB pathogens were evaluated by calculating the MIC decrease factor (MDF). A combination of MEM with either AK or TGC was performed using the checkerboard assay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 21 (35.6%) and 38 (64.4%) CR-GNB isolates were identified as enterobacterial isolates (including 16 (27.1%) <jats:italic>Klebsiella Pneumoniae<\/jats:italic> and 5 (8.5%) <jats:italic>Escherichia coli)<\/jats:italic> and non-fermentative bacilli (including, 23 (39%), <jats:italic>Acinetobacter baumannii<\/jats:italic>, and 15 (25.4%) <jats:italic>Pseudomonas aeruginosa<\/jats:italic>)<jats:italic>.<\/jats:italic> The heatmap and ERIC PCR analysis resulted in non-clonal 28 XDR CR isolates. PR, at a concentration of 0.5\u00a0mg \/ml, decreased MICs values of the tested XDR CR isolates (28; 100%) and restored susceptibility of only 4 (14.3%) isolates. However, PR (1\u00a0mg\/mL) when combined with MEM has completely (28; 100%) restored the susceptibility of the tested XDR CR- GNB to MEM. The MEM\u2009+\u2009AK and MEM\u2009+\u2009TGC combination showed mostly additive effects (92.8% and 71.4%, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PR at a concentration of 1\u00a0mg\/mL restored the susceptibility of XDR CR- GNB to MEM which is considered a promising result that should be clinically investigated to reveal its suitability for clinical use in patients suffering from these life-threatening pathogens.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-023-02934-6","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T08:01:46Z","timestamp":1690012906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin"],"prefix":"10.1186","volume":"23","author":[{"given":"Samar S.","family":"Mabrouk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada R.","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S. Abu","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-850X","authenticated-orcid":false,"given":"Khaled M.","family":"Aboshanab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"issue":"3","key":"2934_CR1","doi-asserted-by":"publisher","first-page":"FSO438","DOI":"10.2144\/fsoa-2019-0098","volume":"6","author":"AA Elshamy","year":"2020","unstructured":"Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Futur Sci OA. 2020;6(3):FSO438. https:\/\/doi.org\/10.2144\/fsoa-2019-0098.","journal-title":"Futur Sci OA"},{"key":"2934_CR2","doi-asserted-by":"publisher","first-page":"823684","DOI":"10.3389\/fcimb.2022.823684","volume":"12","author":"S-S Jean","year":"2022","unstructured":"Jean S-S, Harnod D, Hsueh P-R. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. https:\/\/doi.org\/10.3389\/fcimb.2022.823684.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"2934_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1469-0691.2012.03815.x","volume":"18","author":"P Nordmann","year":"2012","unstructured":"Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2012;18(5):432\u20138. https:\/\/doi.org\/10.1111\/j.1469-0691.2012.03815.x.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2934_CR4","doi-asserted-by":"publisher","first-page":"30461","DOI":"10.2807\/1560-7917.es.2017.22.6.30461","volume":"22","author":"L Dortet","year":"2017","unstructured":"Dortet L, Cuzon G, Ponties V, Nordmann P. Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014. Eurosurveillance. 2017;22(6):30461. https:\/\/doi.org\/10.2807\/1560-7917.es.2017.22.6.30461.","journal-title":"Eurosurveillance."},{"issue":"4","key":"2934_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/jac\/dkx521","volume":"73","author":"H Boutal","year":"2018","unstructured":"Boutal H, Vogel A, Bernabeu S, Devilliers K, Creton E, Cotellon G, et al. A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP-and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(4):909\u201315. https:\/\/doi.org\/10.1093\/jac\/dkx521.","journal-title":"J Antimicrob Chemother"},{"key":"2934_CR6","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.2147\/idr.s229009","volume":"12","author":"C Xin","year":"2019","unstructured":"Xin C, Xia Z, Li G. The impact of pharmaceutical interventions on the use of carbapenems in a Chinese hospital: a pre-post study. Infect Drug Resist. 2019;12:3567. https:\/\/doi.org\/10.2147\/idr.s229009.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"2934_CR7","doi-asserted-by":"publisher","first-page":"e12439","DOI":"10.1111\/dth.12439","volume":"30","author":"HJ Kwon","year":"2017","unstructured":"Kwon HJ, Suh JH, Ko EJ, Kim BJ. Combination treatment of propranolol, minocycline, and tranexamic acid for effective control of rosacea. Dermatol Ther. 2017;30(3):e12439. https:\/\/doi.org\/10.1111\/dth.12439.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2934_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0924-8579(99)00159-4","volume":"14","author":"SG Dastidar","year":"2000","unstructured":"Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN. The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis. Int J Antimicrob Agents. 2000;14(3):249\u201351. https:\/\/doi.org\/10.1016\/s0924-8579(99)00159-4.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2934_CR9","doi-asserted-by":"publisher","first-page":"e0189950","DOI":"10.1371\/journal.pone.0189950","volume":"13","author":"H Nehme","year":"2018","unstructured":"Nehme H, Saulnier P, Ramadan AA, Cassisa V, Guillet C, Eveillard M, et al. Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity. PLoS One. 2018;13(1):e0189950. https:\/\/doi.org\/10.1371\/journal.pone.0189950.","journal-title":"PLoS One"},{"issue":"27","key":"2934_CR10","doi-asserted-by":"publisher","first-page":"e1097","DOI":"10.1097\/md.0000000000001097","volume":"94","author":"P-Y Chang","year":"2015","unstructured":"Chang P-Y, Huang W-Y, Lin C-L, Huang T-C, Wu Y-Y, Chen J-H, et al. Propranolol reduces cancer risk: a population-based cohort study. Medicine (Baltimore). 2015;94(27):e1097. https:\/\/doi.org\/10.1097\/md.0000000000001097.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2934_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jconrel.2003.12.006","volume":"95","author":"A D\u2019emanuele","year":"2004","unstructured":"D\u2019emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control release. 2004;95(3):447\u201353. https:\/\/doi.org\/10.1016\/j.jconrel.2003.12.006.","journal-title":"J Control release"},{"issue":"8","key":"2934_CR12","doi-asserted-by":"publisher","first-page":"e0238195","DOI":"10.1371\/journal.pone.0238195","volume":"15","author":"MA Mohammed","year":"2020","unstructured":"Mohammed MA, Ahmed MT, Anwer BE, Aboshanab KM, Aboulwafa MM. Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones. PLoS One. 2020;15(8):e0238195. https:\/\/doi.org\/10.1371\/journal.pone.0238195.","journal-title":"PLoS One"},{"issue":"3","key":"2934_CR13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4103\/ijmr.ijmr_760_19","volume":"154","author":"A Goel","year":"2021","unstructured":"Goel A, Gupta V, Singhal L, Palta S, Chander J. In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates. Indian J Med Res. 2021;154(3):520\u20136. https:\/\/doi.org\/10.4103\/ijmr.ijmr_760_19.","journal-title":"Indian J Med Res"},{"issue":"2","key":"2934_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1099\/jmm.0.001639","volume":"72","author":"RM Abdel Halim","year":"2023","unstructured":"Abdel Halim RM, Saber SM, Fahim NAE. Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant Acinetobacter species using checkerboard assay. J Med Microbiol. 2023;72(2):1639. https:\/\/doi.org\/10.1099\/jmm.0.001639.","journal-title":"J Med Microbiol"},{"issue":"1","key":"2934_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13205-021-03056-4","volume":"12","author":"A Das","year":"2022","unstructured":"Das A, Sahoo RK, Gaur M, Dey S, Sahoo S, Sahu A, et al. Molecular prevalence of resistance determinants, virulence factors and capsular serotypes among colistin resistance carbapenemase producing Klebsiella pneumoniae: a multi-centric retrospective study. 3 Biotech. 2022;12(1):30. https:\/\/doi.org\/10.1007\/s13205-021-03056-4.","journal-title":"3 Biotech"},{"issue":"11","key":"2934_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/antibiotics10111325","volume":"10","author":"A Mohamed","year":"2021","unstructured":"Mohamed A, Daef E, Nafie A, Shaban L, Ibrahim M. Characteristics of Carbapenem-resistant gram-negative bacilli in patients with ventilator-associated pneumonia. Antibiotics. 2021;10(11):1325. https:\/\/doi.org\/10.3390\/antibiotics10111325.","journal-title":"Antibiotics"},{"key":"2934_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-020-05224-w","volume":"13","author":"B Mirzaei","year":"2020","unstructured":"Mirzaei B, Bazgir ZN, Goli HR, Iranpour F, Mohammadi F, Babaei R. Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran. BMC Res Notes. 2020;13:1\u20136. https:\/\/doi.org\/10.1186\/s13104-020-05224-w.","journal-title":"BMC Res Notes"},{"key":"2934_CR18","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.2147\/idr.s269971","volume":"13","author":"SS Mabrouk","year":"2020","unstructured":"Mabrouk SS, Abdellatif GR, El-Ansary MR, Aboshanab KM, Ragab YM. Carbapenemase producers among extensive drug-resistant gram-negative pathogens recovered from febrile neutrophilic patients in Egypt. Infect Drug Resist. 2020;13:3113\u201324. https:\/\/doi.org\/10.2147\/idr.s269971.","journal-title":"Infect Drug Resist"},{"key":"2934_CR19","unstructured":"Holt JG, Krieg NR, Sneath PHA. Bergey\u2019s manual of determinative bacterology. 9th Edition, Lippincott Williams and Wilkins, Baltimore.1994; (https:\/\/www.scirp.org\/(S(i43dyn45teexjx455qlt3d2q))\/reference\/ReferencesPapers.aspx?ReferenceID=42336; Accessed on 22 Feb 2023)"},{"issue":"4","key":"2934_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/jcp.51.4.316","volume":"51","author":"N Shetty","year":"1998","unstructured":"Shetty N, Hill G, Ridgway GL. The Vitek analyser for routine bacterial identification and susceptibility testing: protocols, problems, and pitfalls. J Clin Pathol. 1998;51(4):316\u201323. https:\/\/doi.org\/10.1136\/jcp.51.4.316.","journal-title":"J Clin Pathol"},{"issue":"3","key":"2934_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A Magiorakos","year":"2012","unstructured":"Magiorakos A, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"2934_CR22","unstructured":"Weinstein MP. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute; 2021. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/ (Accessed on 22 Feb 2022)."},{"issue":"10","key":"2934_CR23","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1128\/jcm.40.10.3798-3801.2002","volume":"40","author":"D Yong","year":"2002","unstructured":"Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-\u03b2-lactamase-producing clinical isolates of Pseudomonas spp and Acinetobacter spp. J Clin Microbiol. 2002;40(10):3798\u2013801. https:\/\/doi.org\/10.1128\/jcm.40.10.3798-3801.2002.","journal-title":"J Clin Microbiol"},{"issue":"12","key":"2934_CR24","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1128\/jcm.01634-13","volume":"51","author":"J Pires","year":"2013","unstructured":"Pires J, Novais A, Peixe L. Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. J Clin Microbiol. 2013;51(12):4281\u20133. https:\/\/doi.org\/10.1128\/jcm.01634-13.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2934_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3390\/antibiotics10050509","volume":"10","author":"NA Kamel","year":"2021","unstructured":"Kamel NA, Elsayed KM, Awad MF, Aboshanab KM, El Borhamy MI. Multimodal interventions to prevent and control Carbapenem-resistant Enterobacteriaceae and extended-spectrum \u03b2-Lactamase producer-associated infections at a tertiary care hospital in Egypt. Antibiotics (Basel). 2021;10(5):509. https:\/\/doi.org\/10.3390\/antibiotics10050509.","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"2934_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12866-022-02660-5","volume":"22","author":"NA Kamel","year":"2022","unstructured":"Kamel NA, Tohamy ST, Yahia IS, Aboshanab KM. Insights on the performance of phenotypic tests versus genotypic tests for the detection of carbapenemase-producing Gram-negative bacilli in resource-limited settings. BMC Microbiol. 2022;22(1):248. https:\/\/doi.org\/10.1186\/s12866-022-02660-5.","journal-title":"BMC Microbiol"},{"issue":"12","key":"2934_CR27","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1128\/jcm.02117-12","volume":"50","author":"D Doyle","year":"2012","unstructured":"Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JDD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol. 2012;50(12):3877\u201380. https:\/\/doi.org\/10.1128\/jcm.02117-12.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"2934_CR28","doi-asserted-by":"publisher","first-page":"e0222168","DOI":"10.1371\/journal.pone.0222168","volume":"14","author":"FS Codjoe","year":"2019","unstructured":"Codjoe FS, Brown CA, Smith TJ, Miller K, Donkor ES. Genetic relatedness in carbapenem-resistant isolates from clinical specimens in Ghana using ERIC-PCR technique. PLoS One. 2019;14(9):e0222168. https:\/\/doi.org\/10.1371\/journal.pone.0222168.","journal-title":"PLoS One."},{"issue":"9","key":"2934_CR29","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1128\/jcm.28.9.1903-1905.1990","volume":"28","author":"PR Hunter","year":"1990","unstructured":"Hunter PR. Reproducibility and indices of discriminatory power of microbial typing methods. J Clin Microbiol. 1990;28(9):1903\u20135. https:\/\/doi.org\/10.1128\/jcm.28.9.1903-1905.1990.","journal-title":"J Clin Microbiol"},{"key":"2934_CR30","unstructured":"Kirkpatrick LA. A simple guide to IBM SPSS statistics-version 23.0. ersion 23.0\u00a014th Edition, Cengage Learning Publisher, Boston, Massachusetts, USA, 2015. https:\/\/www.amazon.com\/Simple-Guide-IBM-SPSS-Statistics\/dp\/1305877713 (Accessed on 22 Feb 2023)"},{"key":"2934_CR31","unstructured":"Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold spring harbor laboratory press, USA; 1989. https:\/\/www.scirp.org\/(S(i43dyn45teexjx455qlt3d2q))\/reference\/ReferencesPapers.aspx?ReferenceID=1480044 (Accessed on 23 Feb 2023)"},{"key":"2934_CR32","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Informational Supplement. CLSI document M100. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. https:\/\/clsi.org\/media\/3481\/m100ed30_sample.pdf (Accessed on 23 Feb 2023)."},{"key":"2934_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1469-0691.2000.00149.x","volume":"9","author":"EUCAST","year":"2003","unstructured":"EUCAST. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID): terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial ag. Clin Microbiol Infec. 2003;9:1\u20137. https:\/\/doi.org\/10.1046\/j.1469-0691.2000.00149.x.","journal-title":"Clin Microbiol Infec"},{"issue":"5","key":"2934_CR34","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/jam.12156","volume":"114","author":"A Huguet","year":"2013","unstructured":"Huguet A, Pensec J, Soumet C. Resistance in Escherichia coli: variable contribution of efflux pumps with respect to different fluoroquinolones. J Appl Microbiol. 2013;114(5):1294\u20139. https:\/\/doi.org\/10.1111\/jam.12156.","journal-title":"J Appl Microbiol"},{"key":"2934_CR35","unstructured":"Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial Combinations. In: Lorian, V., Ed., Antibiotics in Laboratory Medicine, 5th Edition, the Lippincott Williams & Wilkins Co., Philadelphia, USA, 365\u2013440.. https:\/\/www.scirp.org\/(S(351jmbntvnsjt1aadkposzje))\/reference\/referencespapers.aspx?referenceid=1819005 (Accessed on 23 Feb 2023)"},{"issue":"1","key":"2934_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1128\/jcm.43.1.140-143.2005","volume":"43","author":"G Orhan","year":"2005","unstructured":"Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol. 2005;43(1):140\u20133. https:\/\/doi.org\/10.1128\/jcm.43.1.140-143.2005.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"2934_CR37","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1128\/aac.00497-10","volume":"54","author":"MM Sopirala","year":"2010","unstructured":"Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat J-M, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(11):4678\u201383. https:\/\/doi.org\/10.1128\/aac.00497-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2934_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.diagmicrobio.2019.01.020","volume":"94","author":"AM Peri","year":"2019","unstructured":"Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis. 2019;94(4):413\u201325. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.01.020.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2934_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.trsl.2020.02.008","volume":"220","author":"T Brennan-Krohn","year":"2020","unstructured":"Brennan-Krohn T, Manetsch R, O\u2019Doherty GA, Kirby JE. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae. Transl Res. 2020;220:14\u201332. https:\/\/doi.org\/10.1016\/j.trsl.2020.02.008.","journal-title":"Transl Res"},{"issue":"4","key":"2934_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1089\/mdr.2018.0141","volume":"25","author":"AB Benmahmod","year":"2019","unstructured":"Benmahmod AB, Said HS, Ibrahim RH. Prevalence and mechanisms of carbapenem resistance among Acinetobacter baumannii clinical isolates in Egypt. Microb Drug Resist. 2019;25(4):480\u20138. https:\/\/doi.org\/10.1089\/mdr.2018.0141.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"2934_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4037\/ccn2008.28.1.15","volume":"28","author":"K Montefour","year":"2008","unstructured":"Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse. 2008;28(1):15\u201325.","journal-title":"Crit Care Nurse"},{"issue":"1","key":"2934_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11033-018-4515-y","volume":"46","author":"D Zhao","year":"2019","unstructured":"Zhao D, Zuo Y, Wang Z, Li J. Characterize carbapenem-resistant Klebsiella pneumoniae isolates for nosocomial pneumonia and their Gram-negative bacteria neighbors in the respiratory tract. Mol Biol Rep. 2019;46(1):609\u201316. https:\/\/doi.org\/10.1007\/s11033-018-4515-y.","journal-title":"Mol Biol Rep"},{"issue":"9","key":"2934_CR43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/biology10090889","volume":"10","author":"AA Elshamy","year":"2021","unstructured":"Elshamy AA, Saleh SE, Alshahrani MY, Aboshanab KM, Aboulwafa MM, Hassouna NA. OXA-48 Carbapenemase-encoding transferable plasmids of Klebsiella pneumoniae recovered from Egyptian patients suffering from complicated urinary tract infections. Biology (Basel). 2021;10(9):889. https:\/\/doi.org\/10.3390\/biology10090889.","journal-title":"Biology (Basel)"},{"issue":"9","key":"2934_CR44","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1128\/jcm.00901-13","volume":"51","author":"S Pournaras","year":"2013","unstructured":"Pournaras S, Zarkotou O, Poulou A, Kristo I, Vrioni G, Themeli-Digalaki K, et al. A combined disk test for direct differentiation of carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. J Clin Microbiol. 2013;51(9):2986\u201390. https:\/\/doi.org\/10.1128\/jcm.00901-13.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2934_CR45","doi-asserted-by":"publisher","first-page":"114912","DOI":"10.1016\/j.diagmicrobio.2019.114912","volume":"96","author":"JR Cordeiro-Moura","year":"2020","unstructured":"Cordeiro-Moura JR, Fehlberg LCC, Nodari CS, de Matos AP, de Alves VO, Cay\u00f4 R, et al. Performance of distinct phenotypic methods for carbapenemase detection: the influence of culture media. Diagn Microbiol Infect Dis. 2020;96(1):114912. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.114912. Available from.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"20","key":"2934_CR46","doi-asserted-by":"publisher","first-page":"566","DOI":"10.21037\/atm.2019.09.43","volume":"7","author":"J Li","year":"2019","unstructured":"Li J, Li C, Cai X, Shi J, Feng L, Tang K, et al. Performance of modified carbapenem inactivation method and inhibitor-based combined disk test in the detection and distinguishing of carbapenemase producing Enterobacteriaceae. Ann Transl Med. 2019;7(20):566. https:\/\/doi.org\/10.21037\/atm.2019.09.43.","journal-title":"Ann Transl Med"},{"key":"2934_CR47","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/idr.s170233","volume":"11","author":"RA Ramadan","year":"2018","unstructured":"Ramadan RA, Gebriel MG, Kadry HM, Mosallem A. Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations. Infect Drug Resist. 2018;11:1261. https:\/\/doi.org\/10.2147\/idr.s170233.","journal-title":"Infect Drug Resist"},{"issue":"10","key":"2934_CR48","doi-asserted-by":"publisher","first-page":"e0224107","DOI":"10.1371\/journal.pone.0224107","volume":"14","author":"D Biswas","year":"2019","unstructured":"Biswas D, Tiwari M, Tiwari V. Molecular mechanism of antimicrobial activity of chlorhexidine against carbapenem-resistant Acinetobacter baumannii. PLoS One. 2019;14(10):e0224107. https:\/\/doi.org\/10.1371\/journal.pone.0224107.","journal-title":"PLoS One"},{"key":"2934_CR49","doi-asserted-by":"publisher","first-page":"205951311983136","DOI":"10.1177\/2059513119831369","volume":"5","author":"F Falah","year":"2019","unstructured":"Falah F, Shokoohizadeh L, Adabi M. Molecular identification and genotyping of Acinetobacter baumannii isolated from burn patients by PCR and ERIC-PCR. Scars, Burn Heal. 2019;5:2059513119831369. https:\/\/doi.org\/10.1177\/2059513119831369.","journal-title":"Scars, Burn Heal"},{"issue":"24","key":"2934_CR50","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1093\/nar\/19.24.6823","volume":"19","author":"J Versalovic","year":"1991","unstructured":"Versalovic J, Koeuth T, Lupski R. Distribution of repetitive DNA sequences in eubacteria and application to finerpriting of bacterial enomes. Nucleic Acids Res. 1991;19(24):6823\u201331. https:\/\/doi.org\/10.1093\/nar\/19.24.6823.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2934_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/qco.0000000000000109","volume":"27","author":"PI Rafailidis","year":"2014","unstructured":"Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2014;27(6):479\u201383. https:\/\/doi.org\/10.1097\/qco.0000000000000109.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"2934_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3947\/ic.2014.46.3.149","volume":"46","author":"C-S Lee","year":"2014","unstructured":"Lee C-S. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother. 2014;46(3):149\u201364. https:\/\/doi.org\/10.3947\/ic.2014.46.3.149.","journal-title":"Infect Chemother"},{"key":"2934_CR53","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.cmi.2015.11.004","volume":"22","author":"X Guan","year":"2016","unstructured":"Guan X, He L, Hu B, Hu J, Huang X, Lai G, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22:S15-25. https:\/\/doi.org\/10.1016\/j.cmi.2015.11.004.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"2934_CR54","doi-asserted-by":"publisher","first-page":"106344","DOI":"10.1016\/j.ijantimicag.2021.106344","volume":"57","author":"L Scudeller","year":"2021","unstructured":"Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. 2021;57(5):106344. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106344.","journal-title":"Int J Antimicrob Agents."},{"key":"2934_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0369-8114(03)00023-3","volume":"3","author":"GC Leite","year":"2015","unstructured":"Leite GC, Neto LVP, Gaudereto JJ, de MaioCarrilho CMD, Rossi F, Levin AS, et al. Effect of antibiotics combination and comparison of methods for detection of synergism in multiresistant Gram-negative bacteria. J Infect Dis Ther. 2015;3:1\u20139. https:\/\/doi.org\/10.1016\/s0369-8114(03)00023-3.","journal-title":"J Infect Dis Ther"},{"issue":"8","key":"2934_CR56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/antibiotics10081023","volume":"10","author":"P Terbtothakun","year":"2021","unstructured":"Terbtothakun P, Nwabor OF, Siriyong T, Voravuthikunchai SP, Chusri S. Synergistic antibacterial effects of Meropenem in combination with Aminoglycosides against Carbapenem-resistant Escherichia coli harboring bla NDM-1 and bla NDM-5. Antibiotics. 2021;10(8):1023. https:\/\/doi.org\/10.3390\/antibiotics10081023.","journal-title":"Antibiotics"},{"issue":"8","key":"2934_CR57","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14787210.2016.1204911","volume":"14","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Mavroudis AD, Vardakas KZ. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect? Expert Rev Anti Infect Ther. 2016;14(8):747\u201363. https:\/\/doi.org\/10.1080\/14787210.2016.1204911.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"2934_CR58","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1038\/s41598-022-11464-6","volume":"12","author":"YG Ju","year":"2022","unstructured":"Ju YG, Lee HJ, Yim HS, Lee M-G, Sohn JW, Yoon YK. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane\/tazobactam against carbapenem-resistant Acinetobacter baumannii. Sci Rep. 2022;12(1):7541. https:\/\/doi.org\/10.1038\/s41598-022-11464-6.","journal-title":"Sci Rep"},{"issue":"4","key":"2934_CR59","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/mdr.2016.0043","volume":"23","author":"C Shankar","year":"2017","unstructured":"Shankar C, Nabarro LEB, Anandan S, Veeraraghavan B. Minocycline and tigecycline: what is their role in the treatment of carbapenem-resistant gram\u2013negative organisms? Microb Drug Resist. 2017;23(4):437\u201346. https:\/\/doi.org\/10.1089\/mdr.2016.0043.","journal-title":"Microb Drug Resist"},{"issue":"4","key":"2934_CR60","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.ijantimicag.2022.106668","volume":"60","author":"A Antonelli","year":"2022","unstructured":"Antonelli A, Coppi M, Tellapragada C, Hasan B, Maruri A, Gij\u00f3n D, et al. Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem\u2013amikacin and meropenem\u2013colistin combinations against multi-drug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2022;60(4):106668. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106668.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2934_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","volume":"37","author":"S Pournaras","year":"2011","unstructured":"Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time\u2013kill assay. Int J Antimicrob Agents. 2011;37(3):244\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.10.031.","journal-title":"Int J Antimicrob Agents"},{"key":"2934_CR62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s15010-019-01274-w","volume":"47","author":"S Bi","year":"2019","unstructured":"Bi S, Yao X, Huang C, Zheng X, Xuan T, Sheng J, et al. Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection. Infection. 2019;47:497\u2013500. https:\/\/doi.org\/10.1007\/s15010-019-01274-w.","journal-title":"Infection"},{"key":"2934_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fcimb.2019.00193","volume":"9","author":"L Peyclit","year":"2019","unstructured":"Peyclit L, Baron SA, Rolain J-M. Drug repurposing to fight colistin and carbapenem-resistant bacteria. Front Cell Infect Microbiol. 2019;9:193. https:\/\/doi.org\/10.3389\/fcimb.2019.00193.","journal-title":"Front Cell Infect Microbiol"},{"issue":"28","key":"2934_CR64","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.2174\/0929867325666180706101404","volume":"26","author":"AK Konreddy","year":"2019","unstructured":"Konreddy AK, Rani GU, Lee K, Choi Y. Recent drug-repurposing-driven advances in the discovery of novel antibiotics. Curr Med Chem. 2019;26(28):5363\u201388. https:\/\/doi.org\/10.2174\/0929867325666180706101404.","journal-title":"Curr Med Chem"},{"issue":"12","key":"2934_CR65","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/antibiotics9120885","volume":"9","author":"S Herrera-Espejo","year":"2020","unstructured":"Herrera-Espejo S, Cebrero-Cangueiro T, Labrador-Herrera G, Pach\u00f3n J, Pach\u00f3n-Ib\u00e1\u00f1ez ME, \u00c1lvarez-Mar\u00edn R. In vitro activity of pentamidine alone and in combination with antibiotics against multidrug-resistant clinical Pseudomonas aeruginosa strains. Antibiotics. 2020;9(12):885. https:\/\/doi.org\/10.3390\/antibiotics9120885.","journal-title":"Antibiotics"},{"issue":"3","key":"2934_CR66","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/09546634.2017.1360991","volume":"29","author":"K Pietschke","year":"2018","unstructured":"Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat. 2018;29(3):310\u20133. https:\/\/doi.org\/10.1080\/09546634.2017.1360991.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"2934_CR67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/1871526519666181126094244","volume":"20","author":"Y Kapoor","year":"2020","unstructured":"Kapoor Y, Sharma R, Kumar A. Repurposing of existing drugs for the bacterial infections: an in silico and in vitro study. Infect Disord Targets. 2020;20(2):182\u201397. https:\/\/doi.org\/10.2174\/1871526519666181126094244.","journal-title":"Infect Disord Targets"},{"issue":"6","key":"2934_CR68","doi-asserted-by":"publisher","first-page":"0156509","DOI":"10.1371\/journal.pone.0156509","volume":"11","author":"A Sayqal","year":"2016","unstructured":"Sayqal A, Xu Y, Trivedi DK, AlMasoud N, Ellis DI, Rattray NJW, et al. Metabolomics analysis reveals the participation of efflux pumps and ornithine in the response of Pseudomonas putida DOT-T1E cells to challenge with propranolol. PLoS One. 2016;11(6):0156509. https:\/\/doi.org\/10.1371\/journal.pone.0156509.","journal-title":"PLoS One"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-02934-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-023-02934-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-023-02934-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T08:01:52Z","timestamp":1690012912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-023-02934-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2934"],"URL":"https:\/\/doi.org\/10.1186\/s12866-023-02934-6","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, reviewed and approved by the Faculty of Pharmacy, Ain Shams University Research ethics committee, (ACUC-FP-ASU RHDIRB2020110301 REC# 41). A waiving of the patient consent was obtained from the Ain Shams University Research ethics committee since the collected isolates were obtained from the discharged clinical specimens of unidentified patients and there was no any type of contact with patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}